Medical News

RSS

Emdeon Clinician receives Meaningful Use of EHR Technology certification

Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced that Emdeon Clinician™ has been certified to meet Stage 1 Certification Criteria for Meaningful Use of Electronic Health Record (EHR) Technology by the Drummond Group Inc. Emdeon Clinician is a component of Emdeon Office Suite™, which allows healthcare providers to tap into Emdeon's vast network of payers, providers, labs and pharmacies for clinical, financial and administrative healthcare transactions.

25 Oct 2010

CryoLife commences European distribution of PerClot polysaccharide hemostatic agent

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, announced today that it has begun European distribution of PerClot®, a novel polysaccharide hemostatic agent used to control bleeding during surgical procedures or following traumatic injuries.

25 Oct 2010

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Alkermes, Inc. today announced positive topline results from a phase 1 clinical study of an investigational combination of ALKS 33, one of Alkermes' proprietary candidates, and buprenorphine, an existing medication for the treatment of opioid addiction, for the treatment of cocaine addiction.

25 Oct 2010

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

ViroPharma Incorporated today announced that it has completed enrollment in its Phase 2 study evaluating subcutaneous delivery of Cinryze™ (C1esterase inhibitor [human]). This multi-center, open-label, multi-dose Phase 2 study is designed to evaluate the safety, pharmacokinetics and pharmacodynamics of subcutaneous versus intravenous administration of Cinryze in adolescent and adult subjects with hereditary angioedema (HAE).

25 Oct 2010

Marathon running without proper training can damage the heart

Is running a marathon good for you or can it damage the heart?

25 Oct 2010

Safety tips to reduce risk of lead exposure

With more than 2,700 children having elevated blood lead levels in 2009, the Department of Health today reminds parents to test young children for lead exposure, especially during National Lead Poisoning Prevention Week, Oct. 24-30.

25 Oct 2010

Rethink Autism provides free online video to help child with autism for Halloween-related social interactions

How does a family with a child on the autism spectrum participate in Halloween activities. That question is pondered by more families than ever before. The Centers for Disease Control (CDC) estimates that an average of 1 in 110 children in the United States has an Autism Spectrum Disorder (ASD).

25 Oct 2010

EMP named #4 on 'Top 100 Places to Work in Healthcare'

Emergency Medicine Physicians, Ltd. has been named in the Top 100 Places to Work in Healthcare in the United States by Modern Healthcare magazine for the third year consecutively. Only 15 companies nationwide have had that distinction. EMP, whose headquarters are located on Dressler Road in Canton, was ranked number four among companies with 100-999 employees, and number 13 overall in the nation for all participating healthcare companies.

25 Oct 2010

GSA Annual Scientific Meeting to focus on up-to-date news on aging

America's premier authorities on aging will share the most up-to-date news on Social Security, health care reform, the impact of disasters on older people, evolution instruction in classrooms, and other current topics at The Gerontological Society of America's upcoming 63rd Annual Scientific Meeting.

25 Oct 2010

World Vision increases response in cholera affected Haiti

As the cholera outbreak continues to spread in the Artibonite region of Haiti, World Vision is increasing its response in affected areas, pre-positioning much-needed health supplies and preparing residents in its displacement camps in Port-au-Prince with critical, life-saving health and hygiene messages.

25 Oct 2010

Intensive population management program reduces risk of death, health care costs

A new study from Kaiser Permanente Colorado is one of the first to show that an intensive population management program that matches heart disease patients to personal nurses and clinical pharmacy specialists not only reduces the risk of death but reduces health care costs as well.

25 Oct 2010

Brainwave to open twenty first shop at Taunton

On the 29 October 2010, Brainwave will open their twenty first shop at 2 Priorswood Place Taunton, following the success of their existing Taunton store at 106 Roman Road.

25 Oct 2010

Researchers create new high-content assay to increase human embryonic stem cell survival

A new technique for increasing the survival rates of human embryonic stem cells will revolutionize their use in drug discovery and therapy. Human embryonic stem cells often die during the process of isolation using enzymatic disaggregation or low-density plating, which limits their usefulness in drug discovery and basic research. Similarly, the low rate of attachment of implanted cells hinders cell therapy.

25 Oct 2010

Continucare board approves listing on NYSE

Continucare Corporation announced today that its Board of Directors has approved the listing of the Company's common stock on the New York Stock Exchange (NYSE). Subject to the Company's continued compliance with the NYSE's initial listing standards, the Company expects to begin trading on the NYSE on or about November 1, 2010 under its current stock symbol "CNU."

25 Oct 2010

SAIC receives prime follow-on contract to continue biometric support services

Science Applications International Corporation announced today that it was awarded a prime follow-on contract by the U. S. Department of Defense (DoD), Biometrics Identity Management Agency (BIMA) to continue providing biometric support services to the U.S. Central Command's (USCENTCOM) area of responsibility (AOR).

25 Oct 2010

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

Immune Network Ltd. advises that a clinical trial of V5 Immunitor oral vaccine was published earlier this month demonstrating an unexpected powerful effect against tuberculosis, including multi-drug-resistant tuberculosis (MDR-TB) and tuberculosis that is complicated by co-infection with HIV and hepatitis C (HCV).

25 Oct 2010

NeedleTech increases production area with new 73,000-square foot manufacturing facility

U.S. Congressman James McGovern, State Representative Elizabeth Poirier and local dignitaries joined Theragenics Corporation executives in ribbon cutting ceremonies on October 15 for a new 73,000-square foot manufacturing facility for the company's subsidiary, NeedleTech Products. The new facility increases NeedleTech's production area by 30% or 20,000 square feet, allowing the company to consolidate two separate older facilities into one location. The new building will allow NeedleTech to expand operations, increase R&D and offer more services to its customers.

25 Oct 2010

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that brentuximab vedotin (SGN-35) will be featured in three poster presentations at the 8th International Symposium on Hodgkin Lymphoma (ISHL) being held October 23-26, 2010 in Cologne, Germany.

25 Oct 2010

GSN initiates trial of microarray PGD on pregnancy and implantation rates in IVF

Gene Security Network (GSN) announced today that it has initiated enrollment for a prospective randomized trial in collaboration with Ferring Pharmaceuticals to evaluate the impact of GSN's advanced preimplantation genetic diagnosis (PGD) with Parental Support™ on pregnancy and implantation rates in IVF.

25 Oct 2010

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Soligenix, Inc. a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the post-transplantation period.

25 Oct 2010

Medical News

Emdeon Clinician receives Meaningful Use of EHR Technology certification

CryoLife commences European distribution of PerClot polysaccharide hemostatic agent

Positive results from Alkermes combination Phase 1 study of ALKS 33 and buprenorphine for cocaine addiction

Enrollment complete in ViroPharma's Phase 2 study evaluating subcutaneous delivery of Cinryze

Marathon running without proper training can damage the heart

Safety tips to reduce risk of lead exposure

Rethink Autism provides free online video to help child with autism for Halloween-related social interactions

EMP named #4 on 'Top 100 Places to Work in Healthcare'

GSA Annual Scientific Meeting to focus on up-to-date news on aging

World Vision increases response in cholera affected Haiti

Intensive population management program reduces risk of death, health care costs

Brainwave to open twenty first shop at Taunton

Researchers create new high-content assay to increase human embryonic stem cell survival

Continucare board approves listing on NYSE

SAIC receives prime follow-on contract to continue biometric support services

Immune Network enters letter of intent to acquire Immunitor oral vaccine technology

NeedleTech increases production area with new 73,000-square foot manufacturing facility

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

GSN initiates trial of microarray PGD on pregnancy and implantation rates in IVF

Soligenix reports Phase 2 clinical trial results of orBec for GVHD

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News